Webinar Home Page
Integrating Immune Therapies & Targeted Therapies Into Standards of Care for Hematologic and Solid Malignancies 2018
January 1, 2018 – January 1, 2019
Click below to view
Dr. Garon
Webinar #4235a
NON-SMALL CELL LUNG CANCER (NSCLC): What are the standards of care using checkpoint inhibition for treatment-naïve advanced or metastatic patients?
Dr. Garon
Dr. Spigel
Webinar #4235b
NON-SMALL CELL LUNG CANCER (NSCLC): What are the optimal salvage therapies for advanced or metastatic NSCLC patients (of all histologies) who have progressed after any systemic therapy, either monotherapy or any combinations?
Dr. Spigel
Dr. Garon
Webinar #4235c
NSCLC Mini-Questions
Dr. Garon
Dr. West
Webinar #4235d
NON-SMALL CELL LUNG CANCER (NSCLC): What are the newest standards of care for managing EGFR- and ALK-positive advanced or metastatic NSCLC patients in the 1st line setting and for patient after disease progression?
Dr. West
Dr. Bunn
Webinar #4235e
NSCLC Mini-Questions
Dr. Bunn
Dr. Bunn
Webinar #4235f
Expert Panel Discussion and Audience Q & A
Dr. Bunn (Moderator)
Dr. Langer
Webinar #4235g
HEAD & NECK CANCER: Current standards of care and the emerging strategies for advanced or metastatic H&N squamous cell carcinoma
Dr. Langer
Faculty
Webinar #4235h
Expert Panel Discussion and Audience Q & A
Faculty
Dr. Greten
Webinar #4235i
HEPATOCELLULAR CARCINOMA: Integrating the new and emerging immune & targeted therapies into current standards of care.
Dr. Greten
Dr. Abrams
Webinar #4235j
PANCREATIC CANCER: Integrating the advances with translational biology strategies using novel immune and targeted therapies.
Dr. Abrams
Faculty
Webinar #4235k
Expert Panel Discussion and Audience Q & A
Faculty
Dr. Ku
Webinar #4235l
GASTRIC & ESOPHAGEAL CANCERS: Integrating the new and emerging immune & targeted therapies into current standards of care.
Dr. Ku
Dr. Dorf
Webinar #4235m
UROTHELIAL & OTHER BLADDER CANCERS: Integrating the new and emerging immune & targeted therapies into current standards of care.
Dr. Dorf
Dr. Dorf
Webinar #4235n
RENAL CELL CANCER: Integrating the new and emerging immune & targeted therapies into current standards of care.
Dr. Dorf
Dr. Slovin
Webinar #4235o
PROSTATE CANCER: Integrating the new and emerging immune & targeted therapies and chemotherapies into current standards of care.
Dr. Slovin
Faculty
Webinar #4235p
Expert Panel Discussion and Audience Q & A
Faculty
Dr. Gralla
Webinar #4235q
Quality Improvement in Oncology in 2017... and Beyond
Dr. Gralla
Jim Koeller
Webinar #4235r
A New Paradigm in Cancer Care Reimbursement: An Update on MACRA (Medicare Access and CHIP Reauthorization Act) & QPP (Quality Payment Program)
Jim Koeller
Marianne Davies
Webinar #4235s
Immune Therapy Toxicity Management: Nursing Considerations to Improve Patient Outcomes
Marianne Davies
Dr. Gordon
Webinar #4235t
HODGKIN LYMPHOMA: The emerging role of immune therapy
Dr. Gordon
Dr. Armand
Webinar #4235u
NON-HODGKIN LYMPHOMA: What are the roles for Immunotherapy, targeted therapy and chemotherapy for Refractory & Initial Recurrence of DLBCL, Recurrent Follicular Lymphoma/Indolent Lymphoma
Dr. Armand
Dr. Rajkumar
Webinar #4235v
MULTIPLE MYELOMA: Expanding the Therapeutic Options by Targeting SLAMF7, CD38, Checkpoint Inhibition and Other Targets with Immune or Targeted Therapy various combinations.
Dr. Rajkumar
Dr. Jabbour
Webinar #4235w
ACUTE MYELOID LEUKEMIA (AML): Advances with Targeted and Immunotherapy strategies following Allogeneic Stem Cell Transplantation, and used as initial and salvage therapy
Dr. Jabbour
Dr. Jabbour
Webinar #4235x
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): Advances in the Treatment of CLL with Novel Targeted Therapies: Intracellular Targets and Cell Surface targets.
Dr. Jabbour
Dr. Riddell
Webinar #4235y
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) and ACUTE LYMPHOCYTIC LEUKEMIA (ALL): Advances in the Treatment of ALL with Immunotherapies and Targeted Therapies
Dr. Riddell
Faculty
Webinar #4235z
Expert Panel and Audience Q & A
Faculty
Dr. Weber
Webinar #4235aa
Controversy: Should BRAF+MEK or Immunotherapy be the Adjuvant Therapy of Choice for BRAF MT Melanoma?
Dr. Weber